Clinical Trials
BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...
February 13, 2023 | News
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10 In the maintenance phase, filgotinib ...
February 09, 2023 | News
Nectin Therapeutics Ltd. (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology tr...
February 08, 2023 | News
The Collaborative Trajectory Analysis Project (cTAP), a global coalition in rare disease, has announced evidence to support patient-centric alternativ...
February 08, 2023 | News
Amgen (NASDAQ:AMGN) announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the Un...
February 01, 2023 | News
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today repor...
February 01, 2023 | News
Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and ...
February 01, 2023 | News
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced mRNA-1345, an investig...
January 30, 2023 | News
Data derived from the test can help to serve as a critical tool to monitor and help treat HIV-1-infected individuals, as well as inform epidemiologic and g...
January 23, 2023 | News
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a g...
January 23, 2023 | News
Gaucher disease (GD), one of the most common lysosomal storage disorders, is caused by a genetic enzyme deficiency leading to an accumulation of the sphing...
January 20, 2023 | News
This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to p...
January 11, 2023 | News
"This first-in-human study marks the initial therapeutic to be evaluated from Bio4t2's technology," said Dr. Laurence Cooper MD-PhD, Executive Ch...
January 11, 2023 | News
FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee FSD Pharma Inc Announces It Is Investigating Other Products Addre...
January 10, 2023 | News
Most Read
Bio Jobs
News
Editor Picks